Fatty aspirin: A new perspective in the prevention of dementia of Alzheimer's type?

Current Alzheimer Research

Volumn 5, Issue 5, 2008, Pages 422-431

  Pomponi, Massimiliano ^a,b   Gioia, Annamaria Di ^a   Bria, Pietro ^a   Pomponi, Massimo Fabio Lucio ^a  

^a CATHOLIC UNIVERSITY   (Italy)

^b FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

Author keywords

Alzheimer's prevention; Aspirin; Docosahexaenoic acid; Microglia; Synaptogenesis

Indexed keywords

ACETYLSALICYLIC ACID 3 (NITROXYMETHYL)PHENYL ESTER; ALPHA TOCOPHEROL; ASCORBIC ACID; BRAIN DERIVED NEUROTROPHIC FACTOR; DOCOSAHEXAENOIC ACID; DONEPEZIL; LINOLENIC ACID; PLACEBO;

AGED; AGING; ALZHEIMER DISEASE; ARTICLE; BRAIN FUNCTION; CELL ACTIVATION; CELL SURVIVAL; COGNITION; COGNITIVE DEFECT; DIET THERAPY; HIPPOCAMPUS; LIPID PEROXIDATION; MEMORY; MEMORY DISORDER; MICROGLIA; NERVE CELL DEGENERATION; NERVE CELL NETWORK; NERVE CELL PLASTICITY; NERVOUS SYSTEM DEVELOPMENT; NEURITIS; NEUROPROTECTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RISK FACTOR; SYNAPSE; SYNAPTIC TRANSMISSION; SYNAPTOGENESIS;

ALZHEIMER DISEASE; ANIMALS; ANTIOXIDANTS; ASPIRIN; COGNITION DISORDERS; DEMENTIA; DISEASE MODELS, ANIMAL; DOCOSAHEXAENOIC ACIDS; HIPPOCAMPUS; MEMORY; MICE; MICROGLIA; NEUROFIBRILLARY TANGLES; NEURONAL PLASTICITY; SYNAPSES;

EID: 53549093046     PISSN: 15672050     EISSN: None     Source Type: Journal    
DOI: 10.2174/156720508785908892     Document Type: Article

References (111)

1. Parker G, Gibson NA, Brotchie H, Heruc G, Rees AM and Hadzi-Pavlovic D. Omega-3 fatty acids and mood disorders. Am J Psychiatry 163:969-978 (2006).
2. Schaefer EJ, Bongard V, Beiser AS, Lamon-Fava S, Robins SJ, Au R, et al. Plasma phosphatidylcholine docosahexaenoic acid content and risk of dementia and Alzheimer disease: the Framingham Heart Study. Arch Neurol 63(11):1545-1550(2006).
3. Morris MC, Evans DA, Bienias JL, Tangney CC, Bennett DA, Wilson RS, et al. Consumption of fish and n-3 fatty acids and risk of incident Alzheimer disease. Arch Neurol 60:940-946 (2003).
4. Kalmijn S, Launer LJ, Ott A, Witteman JC, Hofman A and Breteler MM. Dietary fat intake and the risk of incident dementia in the Rotterdam Study. Ann Neurol 42:776-782 (1997).
5. Rosenberg RN. Translational Research on the Way to Effective Therapy for Alzheimer Disease. Arch Gen Psychiatry 62:1186-1192(2005).
6. Wyss-Coray T. Inflammation in Alzheimer disease: driving force, bystander or beneficial response? Nat Med 12:1005-1015 (2006).
7. Selkoe DJ. Alzheimer's Disease: Genes, Proteins, and Therapy. Physiol Rev 81:741-766 (2001).
8. Deuss M, Reiss K and Hartmann D. Part-Time alpha-Secretases: The Functional Biology of ADAM 9, 10 and 17. Curr Alzheimer Res 5:187-201 (2008).
9. Steiner H. The Catalytic Core of gamma-Secretase: Presenilin Revisited. Curr Alzheimer Res 5:147-157(2008).
10. Bazan NG. Neuroprotectin D1 (NPD1): a DHA-derived mediator that protects brain and retina against cell injury-induced oxidative stress. Brain Pathol 15:159-166 (2005).
11. McGeer EG and McGeer PL. Inflammatory processes in Alzheimer's disease. Prog. Neuropsychopharmacol. Biol Psychiatry 27:741-749 (2003).
12. Xu J, Chen S, Ku G, Ahmed SH, Xu J, Chen H, et al. Amyloidbeta peptides are cytotoxic to oligodendrocytes. J Neurosci 21: RC118 (2001).
13. Liao YF, Wang BJ, Cheng HT, Kuo LH and Wolfe MS. Tumor necrosis factor-alpha, interleukin-1beta, and interferon-gamma stimulate gamma-secretase-mediated cleavage of amyloid precursor protein through a JNK-dependent MAPK pathway. J Biol Chem 279:49523-49532 (2004).
14. Rao JS, Ertley RN, Lee HJ, DeMar JC Jr, Arnold JT, Rapoport SI, et al. n-3 polyunsaturated fatty acid deprivation in rats decreases frontal cortex BDNF via a p38 MAPK-dependent mechanism. Mol Psychiatry 12:36-46 (2007).
15. Lukiw WJ, Cui JG, Marcheselli VL, Bodker M, Botkjaer A, Gotlinger K, et al. A role for docosahexaenoic acid-derived neuroprotectin D1 in neural cell survival and Alzheimer disease. J Clin Invest 115:2774-2783 (2005).
16. Hof PR and Morrison JH. The aging brain: morphomolecular senescence of cortical circuits. Trends Neurosci 27:607-613 (2004).
17. Calon F, Lim GP, Yang F, Morihara T, Teter B, Ubeda O, et al. Docosahexaenoic acid protects from dendritic pathology in an Alzheimer's disease mouse model. Neuron 43:633-645 (2004).
18. Sakamoto T, Cansev M and Wurtman RJ. Oral supplementation with docosahexaenoic acid and uridine-5'-monophosphate increases dendritic spine density in adult gerbil hippocampus. Brain Res 1182:50-59 (2007).
19. Cole GM and Frautschy SA. Docosahexaenoic acid protects from amyloid and dendritic pathology in an Alzheimer's disease mouse model. Nutr Health 18:249-259 (2006).
20. Arendt T. Alzheimer's disease as a disorder of mechanisms underlying structural brain self-organization. Neuroscience 102:723-765 (2001).
21. Hedden T and Gabrieli JD. Insights into the ageing mind: a view from cognitive neuroscience. Nat Rev Neurosci 5:87-96 (2004).
22. Kojima N, Shirao T. Synaptic dysfunction and disruption of postsynaptic drebrin-actin complex: a study of neurological disorders accompanied by cognitive deficits. Neurosci Res 58:1-5 (2007).
23. Masliah E, Mallory M, Alford M, DeTeresa R, Hansen LA, McKeel DW Jr, et al. Altered expression of synaptic proteins occurs early during progression of Alzheimer's disease. Neurology 56:127-129 (2001).
24. Mora F, Segovia G and del Arco A. Aging, plasticity and environmental enrichment: structural changes and neurotransmitter dynamics in several areas of the brain. Brain Res Rev 55:78-88 (2007).
25. Schinder AF, Gage FH. A hypothesis about the role of adult neurogenesis in hippocampal function. Physiology (Bethesda) 19:253-261 (2004).
26. Bazan NG. Neuroprotectin D1 (NPD1): a DHA-derived mediator that protects brain and retina against cell injury-induced oxidative stress. Brain Pathol 15:159-166 (2005).
27. Hock C, Heese K, Hulette C, Rosenberg C and Otten U. Regionspecific neurotrophin imbalances in Alzheimer disease: decreased levels of brain-derived neurotrophic factor and increased levels of nerve growth factor in hippocampus and cortical areas. Arch Neurol 57:846-51 (2000).
28. Holsinger RM, Schnarr J, Henry P, Castelo VT and Fahnestock M. Quantitation of BDNF mRNA in human parietal cortex by competitive reverse transcription-polymerase chain reaction: decreased levels in Alzheimer's disease. Brain Res Mol Brain Res 76:347-54 (2000).
29. Brenner RR. Factors influencing fatty acid chain elongation and desaturation. In: "The Role of Fats in Human Nutrition". (Eds: Vergroessen AJ and Crawford M), Academic Press, New York; p. 45-72 (1989).
30. Yoshiyama Y, Higuchi M, Zhang B, Yoshiyama Y, Higuchi M, Zhang B, et al. Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model. Neuron 53:337-351 (2007).
31. Kramer JH, Mungas D, Reed BR, Wetzel ME, Burnett MM, Miller BL, et al. Longitudinal MRI and cognitive change in healthy elderly. Neuropsychology 21:412-418 (2007).
32. DiPatre PL and Gelman BB. Microglial cell activation in aging and Alzheimer disease: partial linkage with neurofibrillary tangle burden in the hippocampus. J Neuropathol Exp Neurol 56:143-149 (1997).
33. Hartman TK, Wengenack TM, Poduslo JF and van Deursen JM. Mutant mice with small amounts of BubR1 display accelerated age-related gliosis. Neurobiol Aging 28:921-927 (2007).
34. Hebert LE, Scherr PA, Beckett LA, Albert MS, Pilgrim DM, Chown MJ, et al. Age-specific incidence of Alzheimer's disease in a community population. JAMA 273:1354-1359 (1995).
35. von Strauss E, Viitanen M, De Ronchi D, Winblad B and Fratiglioni L. Aging and the occurrence of dementia. Arch Neurol 56:587-592 (1999).
36. Dufouil C, Clayton D, Brayne C, Chi LY, Dening TR, Paykel ES, et al. Population norms for the MMSE in the very old: estimates based on longitudinal data. Mini-Mental State Examination. Neurology 55:1609-1613 (2000).
37. Paykel ES, Huppert FA and Brayne C. Incidence of dementia and cognitive decline in over-75s in Cambridge: overview of cohort study. Soc Psychiatry Psychiatr Epidemiol 33:387-392 (1998).
38. Peters A, Morrison JH, Rosene DL and Hyman BT. Feature article: Are neurons lost from the primate cerebral cortex during normal aging? Cereb Cortex 8:295-300 (1998).
39. Scheff SW, Price DA, Schmitt FA, DeKosky ST, Mufson EJ, et al. Synaptic alterations in CA1 in mild Alzheimer disease and mild cognitive impairment. Neurology 68:1501-1508 (2007).
40. Small DH. Mechanisms of synaptic homeostasis in Alzheimer's disease. Curr Alzheimer Res 1(1):27-32 (2004).
41. Eriksson PS, Persilieva E, Bjok-Eriksson T, Alborn AM, Nordborg C, Peterson DA, et al. Neurogenesis in the adult human hippocampus. Nat Med 4:1313-1317(1998)
42. Shors TJ, Miesegaes G, Beylin A, Zhao M, Rydel T and Gould E. Neurogenesis in the adult is involved in the formation of trace memories. Nature 410:372-375 (2001).
43. Green P and Yavin E. Mechanisms of docosahexaenoic acid accretion in the fetal brain. J Neurosci Res 52:129-136 (1998).
44. Hashimoto M, Tanabr Y, Fujii Y, Kikuta T, Shibata H and Shido O. Chronic administration of docosahexaenoic acid ameliorates the impairment of statial cognition learning ability in amyloid β-infused rats. J Nutr 135:549-555 (2005).
45. Gamoh S, Hashimoto M, Hossain S and Masumura S. Chronic administration of docosahexaenoic acid improves the performance of radial arm maze task in aged rats. Clin Exp Pharmacol Physiol 28:266-270(2001).
46. Schinder AF and Gage FH. A hypothesis about the role of adult neurogenesis in hippocampal function. Physiology 19:253-261 (2004).
47. Patrylo PR and Williamson A. The effects of aging on dentate circuitry and function. Prog Brain Res 163:679-696 (2007).
48. Xiao Y, Huang Y and Chen ZY. Distribution, depletion and recovery of docosahexaenoic acid are region-specific in rat brain. Br J Nutr 94:544-550 (2005).
49. Connor KM, SanGiovanni JP, Lofqvist C, Aderman CM, Chen J, Higuchi A, et al. Increased dietary intake of omega-3-polyunsaturated fatty acids reduces pathological retinal angiogenesis. Nat Med 13(7):868-873 (2007).
50. Muyllaert D, Terwel D, Krerner A, Sennvik K, Borghgraef P, Devijver H, et al. Neurodegeneration and Neuroinflammation in cdk5/p25-Inducible Mice. A Model for Hippocampal Sclerosis and Neocortical Degeneration. Am J Pathol 172:70-85 (2008).
51. Attems J and Jellinger KA. Hippocampal sclerosis in Alzheimer disease and other dementias. Neurology 5:775 (2006).
52. Pawlosky RJ, Hibbeln JR, Novotny JA and Salem N Jr. Physiological compartmental analysis of alpha-linolenic acid metabolism in adult humans, J Lipid Res 42:1257-1265 (2001).
53. Karten B, Hayashi H, Campenot RB, Vance DE and Vance JE. Neuronal models for studying lipid metabolism and transport. Methods 36:117-128(2005).
54. Igbavboa U, Hamilton J, Kim HY, Sun GY and Wood WG. A new role for apolipoprotein E: modulating transport of polyunsaturated phospholipid molecular species in synaptic plasma membranes. J Neurochem 80(2):255-261 (2002).
55. Jiang CH, Tsien JZ, Schultz PG and Hu Y. The effects of aging on gene expression in the hypothalamus and cortex of mice. Proc Natl Acad Sci USA 98:1930-1934 (2001).
56. Masliah E, Mallory M, Veinbergs I, Miller A and Samuel W. Alterations in apolipoprotein E expression during aging and neurodegeneration. Prog Neurobiol 50:493-503 (1996).
57. Rao JS, Ertley RN, DeMar JC Jr, Rapoport SI, Bazinet RP and Lee HJ. Dietary DHA deprivation alters expression of enzymes of the arachidonic and docosahexaenoic acid cascades in rat frontal cortex. Mol Psychiatry 12:151-157(2007).
58. Cole GM, Lim GP, Yang F, Teter B, Begum A, Ma Q, et al. Prevention of Alzheimer's disease: Omega-3 fatty acid and phenolic anti-oxidant interventions. Neurobiol Aging 26 (Suppl 1):133-136 (2005).
59. Caselli RJ, Beach TG, Yaari R and Reiman EM. Alzheimer's disease a century later. J Clin Psychiatry 67:1784-1800 (2006).
60. Scheff SW, Price DA. Alzheimer's disease-related alterations in synaptic density: neocortex and hippocampus. J Alzheimers Dis 9(3 Suppl):101-115 (2006).
61. Kitajka K, Sinclair AJ, Weisinger RS, Weisinger HS, Mathai M, Jayasooriya AP, et al. Effects of dietary omega-3 polyunsaturated fatty acids on brain gene expression. Proc Natl Acad Sci USA 101:10931-10936 (2004).
62. Mouser PE, Head E, Ha KH and Rohn TT. Caspase-mediated cleavage of glial fibrillary acidic protein within degenerating astrocytes of the Alzheimer's disease brain. Am J Pathol 168:936-946 (2006).
63. Serhan CN, Gotlinger K, Hong S, Lu Y, Siegelman J, Baer T, et al. Anti-inflammatory actions of neuroprotectin D1/protectin D1 and its natural stereoisomers: assignments of dihydroxy-containing docosatrienes. J Immunol 176:1848-1859 (2006).
64. de la Torre JC. Is Alzheimer's disease a neurodegenerative or a vascular disorder? Data, dogma, and dialectics. Lancet Neurol 3:184-190(2004).
65. Cullen KM, Kócsi Z and Stone J. Microvascular pathology in the aging human brain: evidence that senile plaques are sites of microhaemorrhages. Neurobiol Aging 27:1786-1796 (2006).
66. [No authors listed]. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevention trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico. Lancet 354:447-455 (1999).
67. von Schacky C. A review of omega-3 ethyl esters for cardiovascular prevention and treatment of increased blood triglyceride levels. Vase Health Risk Manag 2:251-262 (2006).
68. Jin X, Lok E, Bondy G, Caldwell D, Mueller R, Kapal K, et al. Modulating effects of dietary fats on methylmercury toxicity and distribution in rats. Toxicology 230:22-44 (2007).
69. von Schacky C. Omega-3 fatty acids and cardiovascular disease. Curr Opin Clin Nutr Metab Care 10:129-135 (2007).
70. Mozaffarian D and Rimm EB. Fish intake, contaminants, and human health: evaluating the risks and the benefits. JAMA 296:1885-1899 (2006).
71. Bazan NG. Omega-3 fatty acids, pro-inflammatory signaling and neuroprotection. Curr Opin Clin Nutr Metab Care 10:136-141 (2007).
72. Laskowitz DT, Thekdi AD, Thekdi SD, Han SK, Myers JK, Pizzo SV, et al. Downregulation of microglial activation by apolipoprotein E and ApoE-mimetic peptides. Exp Neurol 167:74-85 (2001).
73. Mori K, Yokoyama A, Yang L, Yang L, Maeda N, Mitsuda N, et al. L-serine-mediated release of apolipoprotein E and lipids from microglial cells. Exp Neurol 185:220-231 (2004).
74. Fiorucci S, Mencarelli A, Meneguzzi A, Lechi A, Renga B, del Soldato P, et al. Co-administration of nitric oxide-aspirin (NO-ASA) and aspirin prevents platelet and monocyte activation and protects against gastric damage induced by aspirin in humans. J Am Coll Cardiol 44:635-641 (2004).
75. Kotilinek LA, Westerman MA, Wang Q, Panizzon K, Lim GP, Simonyi A, et al. Cyclooxygenase-2 inhibition improves amyloidbeta-mediated suppression of memory and synaptic plasticity. Brain 131(Pt 3):651-664 (2008).
76. Lu T, Pan Y, Kao SY, Li C, Kohane I, Chan J, et al. Gene regulation and DNA damage in the ageing human brain. Nature 429:883-891 (2004).
77. Prasad MR, Lovell MA, Yatin M, Dhillon H and Markesbery WR. Regional membrane phospholipid alterations in Alzheimer's disease. Neurochem Res 23:81-88 (1998).
78. Ferri P, Cecchini T, Ambrogini P, Betti M, Cuppini R, Del Grande P, et al. alpha-Tocopherol affects neuronal plasticity in adult rat dentate gyrus: the possible role of PKCdelta. J Neurobiol 66:793-810 (2006).
79. Luchsinger JA, Tang MX, Shea S and Mayeux R. Antioxidant vitamin intake and risk of Alzheimer disease. Arch Neurol 60:203-208 (2003).
80. Laurin D, Masaki KH, Foley DJ, White LR and Launer LJ. Midlife dietary intake of antioxidants and risk of late-life incident dementia: the Honolulu-Asia Aging Study. Am J Epidemiol 159:959-967 (2004).
81. Miller ER III, Pastor-Barriuso R, Dalai D, Riemersma RA, Appel LJ and Guallar E. Meta-analysis: high dosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med 142:37-46 (2005).
82. Zandi PP. Anthony JC, Khachaturian AS, Stone SV, Gustafson D, Tschanz JT, et al. Cache County Study Group. Reduced risk of Alzheimer disease in users of antioxidant vitamin supplements: the Cache County Study. Arch Neurol 61:82-88 (2004).
83. Sano M, Ernesto C, Thomas RG, Klauber MR, Schafer K, Grandman M, et al. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study. NEngl J Med 336:1216-1222 (1997).
84. Sung S, Yao Y, Uryu K, Yang H, Lee VM, Trojanowski JQ, et al. Early vitamin E supplementation in young but not aged mice reduces Abeta levels and amyloid deposition in a transgenic model of Alzheimer's disease. FASEB J 18:323-325 (2004).
85. Masaki KH, Losonczy KG, Izmirlian G, Foley DJ, Ross GW, Petrovitch H, et al. Association of vitamin E and C supplement use with cognitive function and dementia in elderly men. Neurology 54:1265-1272(2000).
86. Ginestet L, Ferrario JE, Raisman-Vozari R, Hirsch EC and Debeir T. Donepezil induces a cholinergic sprouting in basocortical degeneration. J Neurochem 102:434-440 (2007).
87. Greig NH, Giacobini E and Lahiri DK. Advances in Alzheimer therapy: development of innovative new strategies. Curr Alzheimer Res 4:336-339 (2007).
88. Pomponi M, Bria P and Pomponi M. Is Alzheimer's disease a synaptic disorder? J Alzheimers Dis 13:39-47 (2008).
89. Bourre JM. Roles of unsaturated fatty acids (especially omega-3 fatty acids) in the brain at various ages and during ageing. J Nutr Health Aging 8:163-174 (2004).
90. Kumar VB, Vyas K, Buddhiraju M, Alshaher M, Flood JF and Morley JE. Changes in membrane fatty acids and delta-9 desaturase in senescence accelerated (SAMP8) mouse hippocampus with aging. Life Sci 65:1657-1662 (1999).
91. Huettner JE. Kainate receptors and synaptic transmission. Prog Neurobiol 70:387-407 (2003).
92. McGahon BM, Martin DS, Horrobin DF and Lynch MA. Agerelated changes in synaptic function: analysis of the effect of dietary supplementation with omega-3 fatty acids. Neuroscience 94:305-314 (1999).
93. Ahmad A, Murthy M, Greiner RS, Moriguchi T and Salem N Jr. A decrease in cell size accompanies a loss of docosahexaenoate in the rat hippocampus. Nutr Neurosci 5:103-113 (2002).
94. Litman BJ, Niu SL, Polozova A and Mitchell DC. The role of docosahexaenoic acid containing phospholipids in modulating G protein-coupled signaling pathways: visual transduction. J Mol Neurosci 16:237-242 (2001).
95. Bowen RA and Clandinin MT. Dietary low linolenic acid compared with docosahexaenoic acid alter synaptic plasma membrane phospholipid fatty acid composition and sodium-potassium ATPase kinetics in developing rats. J Neurochem 83:764-774 (2002).
96. Vreugdenhil M, Bruehl C, Voskuyl RA, Kang JX, Leaf A and Wadman WJ. Polyunsaturated fatty acids modulate sodium and calcium currents in CA1 neurons. PNAS USA 93:12559-12563 (1996).
97. Kodas E, Vancassel S, Lejeune B, Guilloteau D and Chalon S. Reversibility of n-3 fatty acid deficiency-induced changes in dopaminergic neurotransmission in rats: critical role of developmental stage. J Lipid Res 43:1209-1219 (2002).
98. Wu A, Ying Z and Gomez-Pinilla F. The interplay between oxidative stress and brain-derived neurotrophic factor modulates the outcome of a saturated fat diet on synaptic plasticity and cognition. Eur J Neurosci 19:1699-1707 (2004).
99. Freund-Levi Y, Eriksdotter-Jönhagen M, Cederholm T, Basun H, Faxén-Irving G, Garlind A, et al. Omega-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study: a randomized double-blind trial. Arch Neurol 63:402-408 (2006).
100. Ma QL, Teter B, Ubeda OJ, Morihara T, Dhoot D, Nyby MD, et al. Omega-3 fatty acid docosahexaenoic acid increases SorLA/LR11, a sorting protein with reduced expression in sporadic Alzheimer's disease (AD): relevance to AD prevention. J Neurosci 27:14299-14307 (2007).
101. Rogaeva E, Meng Y, Lee JH, Gu Y, Kawarai T, Zou F, et al. The neuronal sortilin-related receptor SORL1 is genetically associated with Alzheimer disease. Nat Genet 39:168-177 (2007).
102. Spoelgen R, von Arnim CA, Thomas AV, Peltan ID, Koker M, Deng A, et al. Interaction of the cytosolic domains of sorLA/LR11 with the amyloid precursor protein (APP) and beta-secretase betasite APP-cleaving enzyme. J Neurosci 26:418-428 (2006).
103. Jaeger S and Pietrzik CU. Functional role of lipoprotein receptors in Alzheimer's disease. Curr Alzheimer Res 5:15-25 (2008).
104. Plourde M, Fortier M, Vandal M, Tremblay-Mercier J, Freemantle E, Begin M, et al. Unresolved issues in the link between docosahexaenoic acid and Alzheimer's disease. Prostag 77:301-308 (2007).
105. Kalpouzos G, Chételat G, Baron JC, Landeau B, Mevel K, Godeau C, et al. Voxel-based mapping of brain gray matter volume and glucose metabolism profiles in normal aging. Neurobiol Aging Jul. 12; [Epub ahead of print] (2007).
106. Singer W, Panford-Walsh R, Watermann D, Hendrich O, Zimmermann U, Köpschall I, et al. Salicylate alters the expression of calcium response transcription factor 1 in the cochlea: implications for brain-derived neurotrophic factor transcriptional regulation. Mol Pharmacol 73:1085-1091 (2008).
107. Svennerholm L, Bostrom K and Jungbjer B. Changes in weight and compositions of major membrane components of human brain during the span of adult human life of Swedes. Acta Neuropathol (Berlin) 94:345-352 (1997).
108. Favrelère S, Stadelmann-Ingrand S, Huguet F, De Javel D, Piriou A, Tallineau C, et al. Age-related changes in ethanolamine glycerophospholipid fatty acid levels in rat frontal cortex and hippocampus. Neurobiol Aging 21:653-660 (2000).
109. Thal LJ, Kantarci K, Reiman EM, Klunk WE, Weiner MW, Zetterberg H, et al. The role of biomarkers in clinical trials for Alzheimer disease. Alzheimer Dis Assoc Disord 220:6-15 (2006).
110. Lahiri DK, Maloney B, Basha MR, Ge YW and Zawia NH. How and when environmental agents and dietary factors affect the course of Alzheimer's disease: the "LEARn" model (latent earlylife associated regulation) may explain the triggering of AD. Curr Alzheimer Res 4:219-228 (2007).
111. Ebdon L, Foulkes ME, Le Roux S and Muñoz-Olivas R. Cold vapour atomic fluorescence spectrometry and gas chromatographypyrolysis-atomic fluorescence spectrometry for routine determination of total and organometallic mercury in food samples. Analyst 127:1108-1114 (2002).